What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Manufacturing of Biologics Quality Control: A Practical Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Quality Control in Biologics Manufacturing

Quality control (QC) in biologics manufacturing is the systematic set of activities and analytical procedures used to verify that a biological product meets predetermined specifications for identity, purity, potency, and safety. Unlike small-molecule pharmaceuticals, biologics—including monoclonal antibodies, recombinant proteins, vaccines, and cell therapies—are produced by living systems. This introduces inherent variability at every stage, from the master cell bank through the final formulated drug product. QC exists to detect, quantify, and control that variability within established limits.

QC is distinct from quality assurance (QA). QC is operational and laboratory-focused: it involves sampling, testing, and releasing materials and products against defined specifications. QA is a broader, system-level function concerned with the design, implementation, and audit of the entire quality system, including documentation, training, deviation management, and continuous improvement. In practice, QC generates the data; QA interprets the system that produced the data. Both are required under current good manufacturing practice (cGMP), but their roles are complementary rather than interchangeable.

The critical role of QC in biologics cannot be overstated. Because the product is a biological entity, its activity depends on three-dimensional structure, post-translational modifications, and aggregation state—properties that cannot be fully captured by a single analytical method. QC therefore relies on a panel of orthogonal assays that collectively characterize the molecule. A failure in QC can mean releasing a product with reduced efficacy, unexpected immunogenicity, or a contaminant that poses patient risk. Conversely, an over-restrictive QC program can delay release and increase cost without improving patient outcomes. The goal is a scientifically justified, risk-based QC strategy aligned with regulatory expectations.

Scope of QC in Biologics

The scope of QC spans the entire manufacturing lifecycle: incoming raw materials, in-process samples during upstream and downstream processing, the final drug substance, and the formulated drug product. QC also encompasses environmental monitoring of cleanrooms, utilities testing (water for injection, clean steam, gases), and the qualification of analytical instruments. In a typical biologics facility, QC laboratories are organized by discipline—chemistry, microbiology, cell-based assays, and molecular biology—each with its own equipment, methods, and personnel training requirements.

Regulatory Framework (ICH, FDA, EMA)

The regulatory framework for biologics QC is anchored in the International Council for Harmonisation (ICH) guidelines, which are adopted by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national authorities. The most directly relevant guidelines are ICH Q6B (specifications for biotechnological products), ICH Q7 (good manufacturing practice for active pharmaceutical ingredients), and ICH Q11 (development and manufacture of drug substances). These are supplemented by ICH Q2(R2) for analytical method validation and ICH Q5C for stability testing. The FDA additionally enforces 21 CFR Parts 210 and 211 for cGMP, and 21 CFR Part 600 for biological products. The EMA applies equivalent requirements through EudraLex Volume 4. Understanding this framework is essential because QC methods and specifications must be justified to regulators during both the Biologics License Application FDA review process and subsequent inspections.

Critical Quality Attributes and Their Measurement

A critical quality attribute (CQA) is a physical, chemical, biological, or microbiological property or characteristic that must be within an appropriate limit, range, or distribution to ensure the desired product quality. CQAs are identified during product development based on their potential impact on clinical safety and efficacy. For most biologics, the core CQAs fall into four categories: identity, purity, potency, and safety.

Identity Testing

Identity testing confirms that the product is what it is declared to be. For a monoclonal antibody, this typically involves a combination of techniques. Peptide mapping by liquid chromatography-tandem mass spectrometry (LC-MS/MS) after digestion with trypsin generates a sequence-coverage fingerprint that is compared against the expected amino acid sequence. Enzyme-linked immunosorbent assay (ELISA) using anti-idiotype antibodies confirms the specific binding region. For glycoproteins, monosaccharide analysis by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) verifies the expected glycosylation profile. Identity testing is performed on the final drug substance and drug product, and it must be capable of distinguishing the product from structurally similar molecules, including process-related variants.

Purity and Impurity Profiling

Purity testing quantifies the desired product and its variants, while impurity profiling identifies and quantifies process-related and product-related impurities. Product-related impurities include aggregates, fragments, oxidized species, deamidated variants, and misfolded conformers. Process-related impurities include residual host cell proteins (HCPs), host cell DNA, chromatography ligands (e.g., Protein A), and media components.

Size-exclusion chromatography (SEC) with UV detection is the workhorse for aggregate and fragment analysis. A typical SEC method uses a 7.8 × 300 mm column with a mobile phase of 50 mM sodium phosphate, 300 mM sodium chloride, pH 7.0, at a flow rate of 0.5 mL/min. Ion-exchange chromatography (IEX) resolves charge variants: a cation-exchange method using a linear gradient from 10 mM to 500 mM sodium chloride in 20 mM MES, pH 6.0, separates acidic and basic variants from the main peak. Reduced and non-reduced capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) is used for purity assessment at the subunit level, detecting fragments and half-antibodies. For oxidized species, reversed-phase chromatography (RPLC) on a C4 column with a gradient of acetonitrile in 0.1% trifluoroacetic acid is commonly employed.

Mass spectrometry, particularly intact mass analysis by LC-MS, provides a global view of molecular heterogeneity. A typical intact mass analysis uses a quadrupole time-of-flight (QTOF) instrument with a mass range up to 150 kDa, operating in positive ion mode with electrospray ionization. Deconvolution of the charge state envelope reveals the distribution of glycoforms and other post-translational modifications.

Potency Assays

Potency is a measure of the biological activity of the product, expressed relative to a reference standard. For a monoclonal antibody, potency may be measured by a cell-based assay that quantifies antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or receptor blockade. A common format is a reporter gene assay: cells engineered to express the target receptor and a luciferase reporter under the control of a response element are incubated with the antibody. The resulting luminescence signal is proportional to the biological activity. The assay is calibrated against a reference standard, and potency is reported as a percentage of the reference.

For enzymes, potency is typically measured by an enzymatic activity assay. For example, a recombinant lysosomal enzyme may be assayed by incubating with its fluorogenic substrate, such as 4-methylumbelliferyl-α-L-iduronide for iduronidase, and measuring fluorescence at 365 nm excitation and 450 nm emission. The reaction is run at 37°C for 1 hour in 50 mM sodium formate, pH 3.5, and the activity is calculated from a standard curve. For cytokines, potency may be measured by a cell proliferation assay, such as the CTLL-2 cell line for interleukin-2, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction as the readout.

In-Process Controls During Upstream Processing

Upstream processing encompasses cell culture and fermentation, from the thaw of a working cell bank vial through the harvest of the bioreactor. In-process controls (IPCs) during this phase are designed to ensure that the culture is healthy, productive, and free of contamination.

Cell Culture Monitoring

Cell viability and viable cell density are monitored daily using the trypan blue exclusion method with a hemocytometer or, more commonly, an automated cell counter. A typical fed-batch monoclonal antibody culture in a 2,000 L bioreactor is inoculated at 0.3–0.5 × 10⁶ viable cells/mL and reaches a peak density of 10–20 × 10⁶ viable cells/mL before harvest. Viability should remain above 80% at harvest; a rapid decline may indicate nutrient depletion, toxic metabolite accumulation, or infection.

Metabolite monitoring is performed using a blood gas analyzer or a dedicated metabolite analyzer. Glucose, lactate, glutamine, glutamate, and ammonium are measured daily. Glucose is typically maintained above 2 g/L by fed-batch addition; lactate should remain below 2 g/L, as higher concentrations inhibit cell growth and reduce productivity. Ammonium, a byproduct of glutamine metabolism, should be kept below 4 mM. The specific productivity, expressed as picograms of antibody per cell per day (pcd), is calculated from the product titer measured by Protein A HPLC or a rapid immunoassay.

Bioreactor Parameters

Dissolved oxygen (DO) is controlled at 30–50% of air saturation by sparging with oxygen and adjusting the agitation rate. The pH is controlled at 7.0 ± 0.2 by the addition of CO₂ (to lower pH) and sodium carbonate (to raise pH). Temperature is typically maintained at 36.5–37.0°C during growth and may be shifted to 33–35°C during the production phase to reduce cell growth and increase specific productivity. These parameters are logged continuously and reviewed as part of the batch record.

Raw Material Testing

Raw materials, including media components, buffers, and disposable materials, are tested upon receipt. The extent of testing depends on the risk associated with the material. For example, animal-derived components such as fetal bovine serum are tested for mycoplasma, adventitious viruses, and endotoxin. Chemically defined media components are tested for identity, purity, and bioburden. Each lot of a critical raw material is quarantined until it passes the required tests and is approved by QC.

Downstream Processing Quality Control

Downstream processing purifies the product from the harvested cell culture fluid (HCCF) through a series of chromatography, viral inactivation, and filtration steps. QC at this stage focuses on the performance of each step and the removal of process-related impurities.

Chromatography Fraction Analysis

Each chromatography step is monitored by UV absorbance at 280 nm, and the elution pool is collected based on the chromatogram. The collected pool is sampled and tested for product concentration, purity by SEC, and the levels of the specific impurity that the step is designed to remove. For example, after Protein A affinity chromatography, the eluate is tested for residual Protein A by ELISA, with a typical specification of less than 10 ng/mg of product. After a subsequent anion-exchange chromatography step, the flow-through is tested for host cell DNA by quantitative polymerase chain reaction (qPCR), with a typical specification of less than 10 pg/mg of product.

Viral Inactivation and Clearance Testing

Viral clearance is a critical safety attribute for biologics derived from mammalian cell lines. The process must demonstrate the ability to remove or inactivate both endogenous retroviruses and adventitious viruses. This is validated during process development using scale-down models with spiked model viruses, such as murine leukemia virus (MuLV) for retroviruses, minute virus of mice (MVM) for parvoviruses, and reovirus type 3 for reoviruses. The log reduction factor (LRF) for each step is calculated as the log₁₀ of the ratio of virus load before and after the step. A typical process achieves a cumulative LRF of greater than 15 for MuLV across all steps.

During routine manufacturing, the performance of the viral inactivation step is verified by monitoring the pH, temperature, and duration of the low-pH hold. For a typical low-pH viral inactivation step, the Protein A eluate is adjusted to pH 3.5 ± 0.1 with 1 M acetic acid and held for 60 ± 5 minutes at 18–25°C. The pH is then neutralized to pH 7.0 with 2 M Tris base. The step is considered valid if the pH and hold time are within the validated ranges.

Residual Host Cell Protein and DNA Testing

Residual host cell proteins are measured by a multi-analyte ELISA using antibodies raised against a representative HCP preparation from a null cell line. The assay is run in a 96-well plate format, with a typical limit of quantification of 1–5 ng/mL. The specification for residual HCP in the drug substance is typically less than 100 ng/mg of product, though this may be lower for products with a high risk of immunogenicity. Residual host cell DNA is measured by qPCR targeting a multi-copy gene, such as the Alu element for human cell lines or a repetitive element for CHO cells. The specification is typically less than 10 pg/mg of product, in line with WHO recommendations.

Final Product Testing and Release

The final drug substance and drug product undergo a comprehensive battery of tests before release. These tests are defined in the product specification, which is approved by regulatory authorities as part of the marketing authorization.

Sterility and Endotoxin Testing

Sterility testing is performed according to the compendial method described in USP <71> and Ph. Eur. 2.6.1. The method involves inoculating the product into fluid thioglycollate medium and soybean-casein digest medium, followed by incubation at 30–35°C and 20–25°C, respectively, for 14 days. The media are examined for turbidity at regular intervals. For products that are bacteriostatic or fungistatic, a membrane filtration method is used, in which the product is filtered through a 0.45 µm membrane, and the membrane is rinsed with a diluting fluid before being transferred to the culture media.

Endotoxin testing is performed using the limulus amebocyte lysate (LAL) assay, either by the gel-clot method or the chromogenic kinetic method. The test is calibrated against a reference endotoxin standard, and the result is expressed in endotoxin units (EU) per mL. The specification for endotoxin is typically less than 5 EU/kg of body weight per dose, calculated based on the maximum human dose.

Stability Studies

Stability studies are conducted to establish the shelf life of the product and to support the storage conditions stated on the label. The product is stored at the intended storage temperature (typically 2–8°C for liquid formulations) and at accelerated conditions (25°C and 37°C) to predict long-term stability. Samples are pulled at predetermined time points—typically 0, 1, 3, 6, 9, 12, 18, 24, and 36 months—and tested for potency, purity by SEC, charge variants by IEX, and appearance. The stability profile is used to set the expiry date and to support the FDA Post Approval Changes Guidance Biologics if the formulation or manufacturing process is changed.

Batch Release Documentation

Batch release is the final QC decision point. The QC laboratory compiles a certificate of analysis (CoA) that lists each test, the specification, and the result. The CoA is reviewed by the QC unit, and the batch is released by the authorized person (in the EU) or the qualified person (in the US). The release decision is based on the CoA, the in-process control data, the batch record, and the deviation and change control history. Any out-of-specification (OOS) result must be investigated before the batch can be released.

Analytical Method Validation and Transfer

Analytical methods used for QC must be validated to demonstrate that they are suitable for their intended purpose. Validation is performed according to ICH Q2(R2), which defines the parameters to be evaluated.

Validation Parameters

The key validation parameters are accuracy, precision (repeatability and intermediate precision), specificity, linearity, range, limit of detection (LOD), limit of quantitation (LOQ), and robustness. Accuracy is assessed by spiking a known amount of analyte into a placebo or by comparing the method against a reference method. Precision is assessed by analyzing multiple replicates on the same day (repeatability) and on different days by different analysts (intermediate precision). Specificity is demonstrated by showing that the method can distinguish the analyte from related substances, degradation products, and matrix components. Linearity is assessed by analyzing a series of concentrations spanning 50–150% of the expected range and calculating the correlation coefficient, which should be ≥ 0.995. Robustness is assessed by deliberately varying method parameters, such as column temperature, flow rate, and mobile phase pH, and demonstrating that the results are unaffected.

For bioassays, additional parameters include relative accuracy, which is assessed by testing a series of dilutions of the reference standard and comparing the observed potency to the expected potency, and parallelism, which is assessed by comparing the slopes of the dose-response curves of the sample and the reference standard.

Method Transfer Strategies

Method transfer is the process of moving a validated method from the sending laboratory (typically the development laboratory) to the receiving laboratory (typically the QC laboratory). The transfer can be executed by comparative testing, in which both laboratories analyze the same set of samples and the results are compared statistically, or by a partial or full revalidation at the receiving site. A typical comparative transfer protocol specifies the number of batches (at least three), the number of replicates per batch (at least three), and the acceptance criteria. For a quantitative method, the acceptance criteria may be that the difference between the two laboratories' mean results is less than 2% of the mean, or that the 95% confidence interval of the difference falls within ± 2 standard deviations of the combined precision.

Regulatory Expectations and Compliance

Regulatory expectations for biologics QC are defined by ICH guidelines and national regulations. Compliance is assessed through inspections, which may be routine or triggered by a specific event, such as a product recall or a significant change.

ICH Guidelines for Biologics

ICH Q6B provides the framework for setting specifications for biotechnological products. It defines the types of tests that should be included (identity, purity, potency, quantity) and the criteria for setting acceptance limits. ICH Q7 covers GMP for active pharmaceutical ingredients, including biologics, and describes the requirements for QC laboratories, including the need for written procedures, approved specifications, and documented training. ICH Q11 describes the development of the manufacturing process and the identification of CQAs, which form the basis for the control strategy. These guidelines are harmonized across the FDA, EMA, and other regulatory authorities, and they are the primary reference for QC method development and validation.

Data Integrity (ALCOA+)

Data integrity is a cornerstone of regulatory compliance. The ALCOA+ principles require that data be Attributable, Legible, Contemporaneously recorded, Original, and Accurate, and additionally that they be Complete, Consistent, Enduring, and Available. In practice, this means that all QC data must be traceable to the analyst and the instrument, recorded at the time of the analysis, preserved in the original form, and free from errors. Electronic data must be generated by validated systems with audit trails, and access must be restricted to authorized personnel. The FDA has issued a guidance on data integrity, and inspectors routinely scrutinize the data trail during inspections. A single data integrity finding can result in a Form 483 observation, a warning letter, or, in severe cases, a consent decree.

Inspection Preparedness

Inspection readiness is a continuous state, not a one-time event. QC laboratories should maintain an inspection-ready posture by ensuring that all procedures are current, all training is documented, all instruments are qualified and calibrated, and all data are complete and reviewable. A mock inspection, conducted by internal auditors or external consultants, can identify gaps before the actual inspection. During an inspection, the QC laboratory is typically a primary focus, and inspectors will examine the method validation files, the OOS investigation files, the stability data, and the data integrity controls.

Common Pitfalls and Practical Solutions in Biologics QC

Even well-run QC laboratories encounter problems. The following are common failure modes and practical solutions.

Sample Handling Errors

Sample handling errors are a leading cause of invalid results. These include mislabeling, incorrect storage, and improper preparation. For example, a sample that is left at room temperature for several hours before analysis may show elevated aggregation by SEC, leading to a false OOS result. The solution is to implement a chain-of-custody system, with clear labeling, barcoding, and documented storage conditions. Sample preparation should be performed according to a written procedure, and the time between sampling and analysis should be minimized and recorded.

Out-of-Specification (OOS) Investigations

An OOS result is a test result that falls outside the established specification. The initial response is to preserve the sample, the instrument, and the data, and to initiate an investigation. The investigation should first determine whether the OOS is due to a laboratory error (assignable cause) or a product defect. A laboratory investigation includes a review of the analyst's technique, the instrument calibration, the reagents, and the calculations. If a laboratory error is identified, the test is repeated, and the original result is invalidated. If no laboratory error is found, a full-scale investigation is initiated, which may include additional testing, a review of the manufacturing process, and a risk assessment. The investigation must be documented, and the conclusions must be justified. A common mistake is to repeat the test without a formal investigation, which is a violation of cGMP and can lead to regulatory action.

Managing Method Variability

Biological methods, particularly cell-based bioassays, are inherently variable. A typical cell-based potency assay may have an inter-assay coefficient of variation (CV) of 10–20%, compared to 1–2% for a chromatographic method. This variability can lead to OOS results that are not due to a product defect but to method variability. The solution is to establish a robust method with well-defined acceptance criteria for the assay system suitability, such as the signal-to-noise ratio, the slope of the dose-response curve, and the precision of the reference standard replicates. The method should be revalidated if the variability is excessive, and the specification should be set with the method variability in mind.

Frequently Asked Questions

What is the difference between quality control and quality assurance in biologics manufacturing?

Quality control is the operational function that tests materials and products against specifications. It includes sampling, analytical testing, and the release of batches. Quality assurance is the system-level function that ensures the quality system is designed, implemented, and maintained. QA oversees documentation, training, deviation management, and audits. QC generates the data; QA ensures the system that produces the data is compliant.

What are critical quality attributes (CQAs) in biologics?

CQAs are physical, chemical, biological, or microbiological properties that must be within a defined limit to ensure product safety and efficacy. Examples include the amino acid sequence, glycosylation profile, aggregation level, potency, and endotoxin content. CQAs are identified during development and form the basis for the product specification and the control strategy.

How is potency of a biologic measured?

Potency is measured by a bioassay that quantifies the biological activity of the product relative to a reference standard. The assay format depends on the mechanism of action. For a monoclonal antibody, a cell-based assay measuring ADCC, CDC, or receptor blockade may be used. For an enzyme, an enzymatic activity assay with a fluorogenic or chromogenic substrate is typical. The result is expressed as a percentage of the reference standard activity.

What is viral clearance testing and why is it important?

Viral clearance testing demonstrates that the manufacturing process can remove or inactivate viruses that may be present in the cell culture. It is performed during process development using scale-down models spiked with model viruses. The log reduction factor (LRF) is calculated for each step, and the cumulative LRF must meet regulatory expectations. Viral clearance is important because viral contamination can pose a serious patient safety risk.

What are the key ICH guidelines for biologics quality control?

The key guidelines are ICH Q6B (specifications), ICH Q7 (GMP for active ingredients), ICH Q11 (development and manufacture of drug substances), ICH Q2(R2) (method validation), and ICH Q5C (stability). These guidelines are harmonized across the FDA, EMA, and other authorities.

What is an out-of-specification (OOS) result and how should it be handled?

An OOS result is a test result that falls outside the established specification. It must be investigated to determine the cause. The investigation begins with a laboratory investigation to rule out analytical error. If no error is found, a full-scale investigation is initiated, including additional testing and a review of the manufacturing process. The investigation must be documented, and the conclusions must be justified.

How do you validate a bioassay for potency testing?

A bioassay is validated according to ICH Q2(R2), with additional considerations for the biological nature of the assay. Key parameters include accuracy (assessed by testing dilutions of the reference standard), precision (repeatability and intermediate precision), specificity (demonstrated by testing a non-specific control), linearity, range, and robustness. Parallelism between the sample and reference dose-response curves is also assessed.

Key Takeaways

Quality control in biologics is a laboratory-based, operational function distinct from quality assurance, and both are required under cGMP.
CQAs for biologics span identity, purity, potency, and safety, and they are measured by a panel of orthogonal methods including SEC, IEX, CE-SDS, LC-MS, and cell-based bioassays.
In-process controls during upstream and downstream processing ensure process consistency and the removal of process-related impurities, including host cell proteins, DNA, and viruses.
Final product testing includes sterility, endotoxin, appearance, and stability studies, and batch release is a documented decision based on the certificate of analysis and the batch record.
Analytical methods must be validated according to ICH Q2(R2), and methods transferred between laboratories require a formal transfer protocol with defined acceptance criteria.
Regulatory compliance requires adherence to ICH Q6B, Q7, and Q11, and strict data integrity controls per the ALCOA+ principles.
Common pitfalls in biologics QC include sample handling errors, inadequate OOS investigations, and unmanaged method variability; each has practical solutions that should be implemented proactively.